Oncoceutics, Inc. – Glioma

Submitted By:
Published Date:
January 25, 2020

Access Program Information

The objective of this expanded access program is to provide ONC201 on a single patient
compassionate use basis to eligible adult subjects with recurrent glioma that exhibits a
missense histone H3 mutation .

Rare Disease:
Glioma